ARTICLE | Company News

Gilead sales and marketing update

October 12, 2015 7:00 AM UTC

The U.K.’s NICE issued final draft guidance recommending Zydelig idelalisib from Gilead to treat chronic lymphocytic leukemia (CLL). The product is recommended for adults with a 17p deletion or tumor protein p53 (TP53) mutation and have not received any other treatment, or whose cancer has recurred less than 24 months after previous treatment. ...